OA Proteomic Risk Scoring for AA and Joint Replacement Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to accurately determine the risk of developing adjudicated arthropathy (AA) and its progression to total joint replacement (TJR), as well as the treatment response to Nerve Growth Factor (NGF) antagonists or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in subjects with osteoarthritis (OA), necessitating improved predictive tools.
Innovation Solution
Determine an osteoarthritis (OA) proteomic risk score as a weighted aggregate of protein expression or circulating levels to assess the risk of developing AA, progression to TJR, and treatment response to NGF antagonists or NSAIDs, using a composite quantitative measure derived from disease association studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If proteomic risk scores are calculated using specialist knowledge and complex disease association studies, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent creates a simplified copy of the complex proteomic risk assessment by developing a calculable score based on selected protein levels from disease association studies. This copy captures the essential predictive power of comprehensive proteomic analysis while being computationally tractable and clinically implementable.
Solution Approach 2:
The patent extracts the most critical protein markers from extensive disease association studies to construct a focused proteomic risk score. By selecting specific proteins with strong associations to adjudicated arthropathy, the method captures the essential risk information without requiring analysis of all proteomic data.
2Measurement precision
If proteomic data from large cohort studies is included to improve predictive power, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent extracts key proteomic signals from large cohort studies by focusing on specific protein levels that show strong associations with adjudicated arthropathy. This extraction process captures the predictive power of comprehensive proteomic data while reducing the computational burden to manageable levels.
Solution Approach 2:
The patent transforms complex proteomic data into a simplified risk score parameter that can be calculated from selected protein levels. This parameter transformation maintains the predictive information while making the assessment computationally efficient and clinically practical.
Data Source
AI summary
Methods of determining the risk of developing adjudicated arthropathy (AA) and/or progression to total joint replacement (TJR) and determining the treatment response to an NGF antagonist or NSAID treatment in a subject by determination of an OA proteomic risk score for the subject are presented herein.